The UK and US have concluded a landmark commercial pact that will guarantee no duties on British medicine shipments being sold in the US market.
Agreement Details of the Pact
As part of the deal, the UK has pledged to boost expenditure on drugs through the National Health Service (NHS). This commitment ensures that duties on these vital products will remain at zero for a period of the next three years.
This development is in response to previous warnings to significantly raise tariffs on branded drug imports, with figures mentioned up to double the cost.
"This agreement between the Britain strengthens the global environment for cutting-edge drugs and introduces long-overdue equity to American-British pharmaceutical trade," an announcement declared.
Economic Significance
Pharmaceuticals constitute one of the UK's biggest goods shipped to the America, which is easily the primary buyer for leading British pharmaceutical firms.
Trade data show that in the year to the end of last September, the UK exported medicines totaling £11.1bn to the US. This figure accounted for a significant portion of total UK exports in that span.
"This deal safeguards work, stimulates capital expenditure and facilitates the UK to become a worldwide center for medical research," the Business and Trade Secretary remarked.
Detailed British Pledges
The agreement entails several specific changes from the British government:
- Price Threshold Increase: The UK will raise the affordability limit at which it considers new treatments to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a target to raise total health service expenditure on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The amount drug companies must refund to the NHS to control costs will be capped at 15%. Previously, rebates topped 20%.
Broader Context
The deal comes amid a ongoing dispute between the pharmaceutical industry and the UK government over spending levels and approval rates.
These tensions were exacerbated by arguments that US patients were paying several times more for the same drugs than people in the UK and Europe.
Over the last 18 months, several large drug company projects in the UK have been halted or abandoned, while substantial funding commitments have been announced toward US facilities.
The Science Minister publicly accepted that the NHS needed to invest a greater share on drugs, noting that its spending on drugs had declined as a share of its resources over the past decade.
